| Name | Title | Contact Details |
|---|
Get journal articles and books quickly, efficiently and at the lowest cost. Save up to 20% on article spend. Article Galaxy - Research Solutions/Reprints Desk.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
AI-driven data solutions for risk screening, global watchlist search and monitoring (AML/KYC/PEP) and smarter data due diligence.
The Relay2 Cloud WiFi Services solution allows B2C businesses such as retail, hospitality and public venues to deploy OTT WiFi services and mobile applications, including App distribution, advertising, O2O, multicast video and more with unprecedented network efficiency and performance. Similarly, B2B businesses can slash cost of ownership of distributed WLANs and seamlessly integrate office communications services such as site-to-site VPN and VoIP as part of a managed Cloud WiFi service. Relay2 was founded in 2011 by technology leaders with backgrounds at IBM, Nokia and Siemens, and is backed by internationally recognized, top-tier Silicon Valley venture capital firms.